← Leaderboards
Pamela Anne Maher
Virogenics, Inc.
$19,462,030
Attributed
$28,453,650
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,453,650 · 13
By mechanism
R01$12,338,549 · 4
RF1$6,833,981 · 2
U01$3,156,836 · 1
R44$2,432,649 · 1
R21$1,591,700 · 3
R42$1,499,999 · 1
Top collaborators
- David R Schubert8 shared
- William C Raschke7 shared
- Wolfgang H Fischer1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPreventS DiseasePharmaceutical PreparationsAnimalsClinical TrialsBrainMouse ModelNeurodegenerative DisordersAge RelatedBaseNeuronsDrug CandidatePathologyPathway InteractionsToxic EffectProteinsLongevityCognitionLaboratoriesSmall MoleculeClinicAnimal ModelDrug Discovery
Grant awards (30)
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,562,187
U01 · FY2025 · AG
Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease$2,432,649
R44 · FY2024 · AG
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,594,649
U01 · FY2024 · AG
Using geroscience to understand and treat Alzheimer's disease$769,073
R01 · FY2024 · AG · contact PI
Using geroscience to understand and treat Alzheimer's disease$766,730
R01 · FY2023 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,338,814
R01 · FY2022 · AG
Using geroscience to understand and treat Alzheimer's disease$766,091
R01 · FY2022 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$251,666
R01 · FY2022 · AG
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$210,130
R01 · FY2022 · AG
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,503,169
R01 · FY2021 · AG
Using geroscience to understand and treat Alzheimer's disease$815,791
R01 · FY2021 · AG · contact PI
Using geroscience to understand and treat Alzheimer's disease$843,328
R01 · FY2020 · AG · contact PI
Therapeutic Relevance of Cannabinoids for Alzheimer's Disease$529,100
R21 · FY2020 · AG · contact PI
The Contribution of Kidney Disease to Age-Associated Cognitive Decline$3,189,011
RF1 · FY2019 · AG · contact PI
A Novel Drug Candidate for the Treatment of Huntington's Disease$240,500
R21 · FY2019 · NS · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$505,457
R01 · FY2018 · AG
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2018 · AG
A Novel Drug Candidate for the Treatment of Huntington's Disease$288,600
R21 · FY2018 · NS · contact PI
The Contribution of Old Age-Associated Proteotoxicity to Inflammation and Dementia$3,644,970
RF1 · FY2017 · AG · contact PI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$728,550
R42 · FY2017 · AI · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2017 · AG
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$771,449
R42 · FY2016 · AI · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2016 · AG
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$470,450
R01 · FY2015 · AG
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2014 · AG
Modulation of the Innate Immune System by Fisetin for the Treatment of AD$299,968
R41 · FY2014 · AI · contact PI
Protein Glycation and the Proteasome: Role in Neurological Diseases and Aging$242,500
R21 · FY2014 · AG · contact PI
Modulation of the Innate Immune System by Fisetin for the Treatment of AD$299,968
R41 · FY2013 · AI · contact PI
Protein Glycation and the Proteasome: Role in Neurological Diseases and Aging$291,000
R21 · FY2013 · AG · contact PI
REGULATION OF FGF ACTIVITY BY FGF RECEPTOR SIGNALING$157,850
R01 · FY2000 · GM